Trials that use: Risk ratio / relative risk
New to this method? Read the tutorial →
6,204 results
- SOPRAIndependent statistical analysis of Selinexor (KPT-330) in Older Patients With Relapsed AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02088541).
- Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01510756).
- Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00126568).
- Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496756).
- Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00131911).
- Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00131937).
- Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SPAFIndependent statistical analysis of Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SPARCIndependent statistical analysis of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SPARCIndependent statistical analysis of Sustaining Patient-centered Alcohol-related Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02675777).
- SPARKIndependent statistical analysis of Kuvan® in Phenylketonuria Patients Less Than 4 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01376908).
- SPARKLEIndependent statistical analysis of Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SPARTANIndependent statistical analysis of Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion “Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma”: Complete Statistical AnalysisIndependent statistical analysis of Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma": primary endpoint results, effect estimate with confidence…
- Special Drug Use Surveillance of Vonoprazan for “Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use”: Complete Statistical AnalysisIndependent statistical analysis of Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use": primary endpoint results, effect estimate with confidence…
- Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation): Complete Statistical AnalysisIndependent statistical analysis of Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01329380).
- Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan): Complete Statistical AnalysisIndependent statistical analysis of Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Special Survey on Parkinson’s Disease (PD) Patients Without Concomitant Use of L-Dopa: Complete Statistical AnalysisIndependent statistical analysis of Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Specificity Trial of the Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Specificity Trial of the Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Specified Drug-Use Survey of Trelagliptin Tablets “Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease”: Complete Statistical AnalysisIndependent statistical analysis of Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease": primary endpoint results, effect…
- SPECSIndependent statistical analysis of SPECS: Safe Pediatric Euglycemia in Cardiac Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00443599).
- SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Spectroscopy Versus Standard Care in Cervical Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Spectroscopy Versus Standard Care in Cervical Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00529464).
- SPEEDIndependent statistical analysis of Patient Actor Training to Improve HIV Services for Adolescents in Kenya: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02978690).
- SPETIndependent statistical analysis of Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- SPGblockIndependent statistical analysis of Sphenopalatine Ganglion Blocks RCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03666663).
- SPINSIndependent statistical analysis of Stress CMR Perfusion Imaging in the United States (SPINS) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03192891).
- SPIRITIndependent statistical analysis of A Representational Intervention to Promote Preparation for End-of-life Decision Making: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01259011).
- SPIRITIndependent statistical analysis of Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00244842).
- SPIRITIndependent statistical analysis of Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SPIRIT SVIndependent statistical analysis of SPIRIT Small Vessel Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00783796).
- SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study): Complete Statistical AnalysisIndependent statistical analysis of SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study): primary…
- Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy: Complete Statistical AnalysisIndependent statistical analysis of Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Split-DoseIndependent statistical analysis of Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SpO2 System Accuracy Testing With Different Sensors: Complete Statistical AnalysisIndependent statistical analysis of SpO2 System Accuracy Testing With Different Sensors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01613222).
- SpO2 Validation of Noninvasive Red Diamond Disposable Pulse Oximeter Sensor: Complete Statistical AnalysisIndependent statistical analysis of SpO2 Validation of Noninvasive Red Diamond Disposable Pulse Oximeter Sensor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03124602).
- SPOTLIGHT203Independent statistical analysis of BO-112 With Pembrolizumab in Unresectable Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04570332).
- SPPIndependent statistical analysis of Supporting Parents Program: Intervention for Families in CPS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01332851).
- SPP2Independent statistical analysis of Effect of Behavioral Nudges on Serious Illness Conversation Documentation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04867850).
- Sprifermin (AS902330) in Cartilage Injury Repair (CIR): Complete Statistical AnalysisIndependent statistical analysis of Sprifermin (AS902330) in Cartilage Injury Repair (CIR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01066871).
- SPRINGIndependent statistical analysis of High-Risk Neuroblastoma Chemotherapy Without G-CSF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02786719).
- SPRING-2Independent statistical analysis of A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…